Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8907099 | NEUROCRINE | Nitrocatechol derivatives as COMT inhibitors |
May, 2027
(3 years from now) | |
US8168793 | NEUROCRINE | Nitrocatechol derivatives as COMT inhibitors |
Apr, 2029
(4 years from now) | |
US9630955 | NEUROCRINE | Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor |
Dec, 2032
(8 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9550759 | NEUROCRINE | Nitrocatechol derivatives as COMT inhibitors |
Jul, 2026
(2 years from now) | |
US9745290 | NEUROCRINE | Dosage regimen for COMT inhibitors |
Oct, 2027
(3 years from now) | |
US8524746 | NEUROCRINE | Dosage regimen for COMT inhibitors |
Jul, 2029
(5 years from now) | |
US10583130 | NEUROCRINE | Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof |
Mar, 2030
(5 years from now) | |
US10071085 | NEUROCRINE | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof |
Mar, 2030
(5 years from now) | |
US10357468 | NEUROCRINE | Medicaments for slowing Parkinson's disease |
May, 2035
(11 years from now) |
Ongentys is owned by Neurocrine.
Ongentys contains Opicapone.
Ongentys has a total of 9 drug patents out of which 0 drug patents have expired.
Ongentys was authorised for market use on 24 April, 2020.
Ongentys is available in capsule;oral dosage forms.
Ongentys can be used as method of reducing o-methylation of l-dopa, adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease, method of treating parkinson's disease.
Drug patent challenges can be filed against Ongentys from 24 April, 2024.
The generics of Ongentys are possible to be released after 27 May, 2035.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Apr 24, 2025 |
Drugs and Companies using OPICAPONE ingredient
NCE-1 date: 24 April, 2024
Market Authorisation Date: 24 April, 2020
Treatment: Method of reducing o-methylation of l-dopa; Method of treating parkinson's disease; Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease
Dosage: CAPSULE;ORAL